Brief: Bioinvent: Positive Interim Results From The Phase I/IIa Trial

BioInvent International AB

28/01/2021 06:51

Jan 28 (Reuters) - BioInvent International AB  BINV.ST :
    * BIOINVENT PHASE I/IIA DATA SUGGEST BI-1206 RESTORES
ACTIVITY OF
RITUXIMAB IN RELAPSED NON-HODGKIN'S LYMPHOMA PATIENTS
    * LONG-LASTING COMPLETE RESPONSES OBSERVED IN TWO
PATIENTSBEYOND
12 MONTHS
    * RESPONSES IN 6 OUT OF 9 PATIENTS EVALUATEDPROVIDE EXCITING
EVIDENCE THAT BI-1206 HAS POTENTIAL TO RESTORE ACTIVITY OF
RITUXIMAB IN NON-HODGKIN'S LYMPHOMA PATIENTS WHO HAVE RELAPSED
AFTER TREATMENT WITH RITUXIMAB
    * NO DOSE-LIMITING TOXICITIES HAVE BEEN OBSERVED IN FIVE
PATIENTS
WHO HAVE BEEN TREATED UNDER CURRENT PROTOCOL, DESPITE RECEIVING
HIGHER DOSES OF BI-1206

Source text for Eikon:  ID:nWkr9qPt3N 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))